Find Information About:

Drugs & Supplements

Get information and reviews on prescription drugs, over-the-counter medications, vitamins, and supplements. Search by name or medical condition.

Pill Identifier

Pill Identifier

Having trouble identifying your pills?

Enter the shape, color, or imprint of your prescription or OTC drug. Our pill identification tool will display pictures that you can compare to your pill.

Get Started
My Medicine

My Medicine

Save your medicine, check interactions, sign up for FDA alerts, create family profiles and more.

Get Started

WebMD Health Experts and Community

Talk to health experts and other people like you in WebMD's Communities. It's a safe forum where you can create or participate in support groups and discussions about health topics that interest you.

  • Second Opinion

    Second Opinion

    Read expert perspectives on popular health topics.

  • Community


    Connect with people like you, and get expert guidance on living a healthy life.

Got a health question? Get answers provided by leading organizations, doctors, and experts.

Get Answers

Sign up to receive WebMD's award-winning content delivered to your inbox.

Sign Up

Colorectal Cancer Health Center

Font Size

Gene Test Predicts Return of Colon Cancer

Test Called Oncotype DX Could Help Patients Decide if Chemotherapy Is Needed
WebMD Health News
Reviewed by Louise Chang, MD

May 14, 2009 -- A test that characterizes each tumor by its genetic signature may soon help some colon cancer patients decide whether to have chemotherapy after surgery or whether they can safely forgo additional treatment.

Called Oncotype DX, the test predicts the chance that cancer will come back after surgery alone in people with stage II colon cancer.

"This test empowers doctors and their patients to make more informed decisions about chemotherapy after surgery," says researcher David Kerr, MD, professor of cancer medicine at the University of Oxford.

If its name sounds familiar, that's because the new test is a version of the Oncotype DX breast cancer test that is already being used to guide the treatment of estrogen-fueled breast cancers that have not spread to the lymph nodes.

The version for colon cancer patients is expected to be available next year, according to Genomic Health, which makes both tests and funded the work.

Kerr discussed a new study on the colon cancer test at a news conference sponsored by the American Society of Clinical Oncology (ASCO).

Risk of Cancer Recurrence

About 25%-30% of people diagnosed with colon cancer have stage II disease. That means the cancer has spread through the wall of the colon and may have spread to nearby tissues or organs, but has not spread to the nearby lymph nodes or distant areas.

Although most people with stage II colon cancer are cured after surgery alone, about 20%-25% experience a recurrence of cancer.

The problem: "There's no good tool to tell us who will have a recurrence after surgery and who won't," says ASCO President Richard L. Schilsky, MD, professor of medicine at the University of Chicago. He was not involved with the work.

That's where the new test, which looks at the activity of a dozen genes involved in colon cancer risk, comes in.

For the study, the researchers analyzed 761 genes from 1,851 patients with stage II colon cancer and identified 12 genes with the potential to predict the likelihood of cancer recurrence.

Then, they analyzed tissue samples collected from 711 people who had undergone surgery for stage II colon cancer.

Today on WebMD

Colorectal cancer cells
The right diagnosis is the most important factor.
man with a doctor
Our health check will steer you in the right direction.
sauteed cherry tomatoes
Fight cancer one plate at a time.
bladder cancer x-ray
Do you know the warning signs?
Colon vs Rectal Cancer
New Colorectal Treatments
can lack of sleep affect your immune system
Cancer Facts Quiz
Virtual Colonoscopy
Picture of the Colon
Vitamin D